Department of Genetics, Environment and Evolution, University College London Genetics Institute, Gower St, London WC1E 6BT, UK.
Eur Heart J. 2013 Apr;34(13):972-81. doi: 10.1093/eurheartj/ehs243. Epub 2012 Sep 13.
The aim of this study was to quantify the collective effect of common lipid-associated single nucleotide polymorphisms (SNPs) on blood lipid levels, cardiovascular risk, use of lipid-lowering medication, and risk of coronary heart disease (CHD) events.
Analysis was performed in two prospective cohorts: Whitehall II (WHII; N = 5059) and the British Women's Heart and Health Study (BWHHS; N = 3414). For each participant, scores were calculated based on the cumulative effect of multiple genetic variants influencing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Compared with the bottom quintile, individuals in the top quintile of the LDL-C genetic score distribution had higher LDL-C {mean difference of 0.85 [95% confidence interval, (CI) = 0.76-0.94] and 0.63 [95% CI = 0.50-0.76] mmol/l in WHII and BWHHS, respectively}. They also tended to have greater odds of having 'high-risk' status (Framingham 10-year cardiovascular disease risk >20%) [WHII: odds ratio (OR) = 1.36 (0.93-1.98), BWHHS: OR = 1.49 (1.14-1.94)]; receiving lipid-lowering treatment [WHII: OR = 2.38 (1.57-3.59), BWHHS: OR = 2.24 (1.52-3.29)]; and CHD events [WHII: OR = 1.43 (1.02-2.00), BWHHS: OR = 1.31 (0.99-1.72)]. Similar associations were observed for the TC score in both studies. The TG score was associated with high-risk status and medication use in both studies. Neither HDL nor TG scores were associated with the risk of coronary events. The genetic scores did not improve discrimination over the Framingham risk score.
At the population level, common SNPs associated with LDL-C and TC contribute to blood lipid variation, cardiovascular risk, use of lipid-lowering medications and coronary events. However, their effects are too small to discriminate future lipid-lowering medication requirements or coronary events.
本研究旨在定量评估常见脂质相关单核苷酸多态性(SNP)对血脂水平、心血管风险、降脂药物使用和冠心病(CHD)事件风险的综合影响。
在两个前瞻性队列中进行了分析:Whitehall II(WHII;N=5059)和英国女性心脏与健康研究(BWHHS;N=3414)。对于每个参与者,根据影响总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和甘油三酯(TG)的多种遗传变异的累积效应计算了分数。与 LDL-C 遗传评分分布的最低五分位相比,最高五分位的个体 LDL-C 水平更高{WHII 中分别为 0.85[95%置信区间(CI)=0.76-0.94]和 0.63[95%CI=0.50-0.76]mmol/L}。他们也更有可能处于“高风险”状态(弗雷明汉 10 年心血管疾病风险>20%)[WHII:比值比(OR)=1.36(0.93-1.98),BWHHS:OR=1.49(1.14-1.94)];接受降脂治疗[WHII:OR=2.38(1.57-3.59),BWHHS:OR=2.24(1.52-3.29)];以及 CHD 事件[WHII:OR=1.43(1.02-2.00),BWHHS:OR=1.31(0.99-1.72)]。在这两项研究中,TC 评分也观察到类似的关联。TG 评分与两项研究中的高风险状态和药物使用相关。HDL 或 TG 评分均与冠状动脉事件风险无关。遗传评分并不能提高弗雷明汉风险评分的区分能力。
在人群水平上,与 LDL-C 和 TC 相关的常见 SNP 有助于血脂变化、心血管风险、降脂药物使用和冠心病事件。然而,它们的影响太小,无法区分未来降脂药物的需求或冠状动脉事件。